BIOMAT Database Logo BIOMAT Database Logo

Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents. 1994

A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
Department of Gynecology and Obstetrics, St. Vincentius-Krankenhaus, Karlsruhe, Germany.

Platinum-based polychemotherapy is widely used in the treatment of gynecological cancer. Emesis is one of the most disturbing side-effects of platinum therapy. We performed a study to evaluate and compare the emetogenic potential and the different emesis pattern after cisplatin and carboplatin under antiemetic treatment with ondansetron. One hundred and twenty-two patients with either cisplatin-containing (n = 70) or carboplatin-containing (n = 52) first-line chemotherapy were included. Treatment with cisplatin led more frequently to emesis and patients suffered from more severe emesis than carboplatin treated patients. Delayed emesis was observed after both platinum analogues but occurred more frequently and lasted longer after cisplatin.

UI MeSH Term Description Entries
D007069 Ifosfamide Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent. Isofosfamide,Isophosphamide,Asta Z 4942,Holoxan,Iphosphamide,Iso-Endoxan,NSC-109,724,NSC-109724,Iso Endoxan,NSC 109,724,NSC 109724,NSC109,724,NSC109724
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer.
February 1986, British journal of urology,
A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
Comparative nephrotoxicity of carboplatin and cisplatin in combination with tobramycin.
January 1986, Cancer chemotherapy and pharmacology,
A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
Combination therapy with nucleoside analogs and alkylating agents.
April 1994, Leukemia,
A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
Mechanisms of resistance to cisplatin and alkylating agents.
January 1989, Cancer treatment and research,
A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer.
January 2013, Drug design, development and therapy,
A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
[Probability of the combination use of cisplatin and carboplatin].
November 1990, Nihon Gan Chiryo Gakkai shi,
A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
A comparison between two alkylating agents: CB 3210 and cyclophosphamide.
January 1965, Oncologia,
A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
Comparison of Efficacy and Safety between Carboplatin-Etoposide and Cisplatin-Etoposide Combination Therapy in Patients with Advanced Neuroendocrine Carcinoma: A Retrospective Study.
January 2024, Oncology,
A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
February 1992, Seminars in oncology,
A du Bois, and W Vach, and C Thomssen, and U Karck, and H Madjar, and H Prömpeler, and H G Meerpohl
[Comparison between carboplatin and cisplatin plus etoposide and carboplatin plus etoposide in the treatment of small cell lung cancer.].
December 1999, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
Copied contents to your clipboard!